News & Press

Filter by year:

GeNeuro reports cash and revenue for Q3 2017

Geneva, Switzerland, 2 November 2017 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis and type-1 diabetes, reported today its cash and revenues for the third quarter 2017.

GeNeuro to Host Conference Call and Webcast Today Following the Presentation of Promising Post-Hoc Analyses at the MSParis2017 Congress

Geneva, Switzerland, 30 October 2017 at 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, reported promising post-hoc analyses of six-month data from CHANGE-MS Phase 2b study at MSParis2017 on Saturday October 28th and will hold a conference call and webcast today.

Presentation of Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017

 

GeNeuro and Servier Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017

Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results showed an anti-inflammatory effect in active patients at the highest (18 mg/kg) of the three doses tested at Week 24. In addition, at the same dose, a promising effect on remyelination was observed at 24 weeks.

GeNeuro Reports 2017 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, 28 September 2017 at 06:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, today reported its half-year financial results for the period ending June 30, 2017 and provided a corporate update.

GeNeuro and Servier to Present Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis at MSParis2017

Geneva, Switzerland, and Paris, France - 19 Septembre 2017 at 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today that 6-month data from the CHANGE-MS Phase 2b study will be presented at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS meeting held 25-28 October 2017, in Paris, France. The presentation will cover efficacy and safety data, and will include post-hoc analyses supporting the hypothesis of a

[An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes].

Levet S, Medina J, Joanou J, Demolder A, Queruel N, Réant K, Normand M, Seffals M, Dimier J, Germi R, Piofczyk T, Portoukalian J, Touraine JL, Perron H

JCI Insight. 2017;2(17):e94387. 

GeNeuro and Collaborators Publish Data Supporting Role of Retroviral Pathogenic Envelope Protein in Type 1 Diabetes (T1D)

Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that data supporting the role of pathogenic pHERV-W env in Type 1 diabetes has been published in The Journal of Clinical Investigation Insight. Pathogenic pHERV-W env is encoded by a member of the HERV-W family. HERVs are ancestral retroviral DNA insertions in the human genome, thought to account for up to 8% of the human genome.

GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis

Geneva, Switzerland, and Paris, France, 28 August 2017 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today 6-month results from the 12-month CHANGE-MS Phase 2b study of three doses of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

GeNeuro updates on cash, revenue and activities at Q2 2017

Genève, Switzerland, 31 July 2017 - 6:00pm CEST : GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis and type-1 diabetes, reports today on its cash and revenues for the second quarter 2017 and provides an update on its activities.


Results 1-10 of 21      Next Page      Last Page